Cancer Pain Market Report and Forecast 2025-2034

The cancer pain market attained a value of USD 6.53 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 6.10%, to reach USD 11.81 Billion by 2034.

Cancer Pain Market Overview

Cancer pain can result from a tumor pressing on organs, nerves, or bones. It can also be caused by cancer treatments or surgery. The severity of pain can differ depending on factors such as the type of cancer and its stage. The rising prevalence of cancer necessitates the need for effective therapeutics to manage cancer pain. With the global burden of new cancer cases predicted to reach approximately 30 million by 2040, the cancer pain market demand is anticipated to surge in the forecast period.

The increased impetus for research activities to address the growing need for cancer pain treatment solutions has bolstered market growth. Intensive research efforts are paving the way for potential therapeutics. According to a study published in BMJ Supportive & Palliative Care in May 2023, medical cannabis was revealed to be safe and effective for treating cancer-related pain. Further, the use of medical cannabis reduced the use of opioids and other pain medications by almost 32%. Thus, the introduction of such products in cancer patients’ pain regimens is likely to augment the cancer pain market growth.

The market is also driven by the rising healthcare expenditure to treat cancer-associated pain as well as various initiatives and programs launched by the government to raise awareness regarding the condition. Moreover, the rising geriatric population with increased susceptibility to cancer pain will also help in the market growth.

Cancer Pain Market Segmentation

Cancer Pain Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Type

• Opioids
• Fentanyl
• Morphine
• Others
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drug
• Nerve Blockers

Based on the drug type, the market is divided into opioids, non-opioids, and nerve blockers. Opioids such as fentanyl and morphine, among others, can help manage moderate to severe pain. Non-opioids like acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are used to reduce inflammation and block pain signals without targeting opioid receptors. Nerve blockers help in blocking nerve signals responsible for pain transmission.

Market Breakup by Indication Type

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

The market segmentation by indication type includes lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The rising prevalence of different types of cancer is fueling the cancer pain market share.

Market Breakup by Treatment Type

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Hormonal Therapy

The market segmentation by treatment type comprises immunotherapy, chemotherapy, targeted therapy, and hormonal therapy. Each treatment type has unique mechanisms of action as well as potential side effects.

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

The market report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market which can be attributed to the rising geriatric population, the presence of an advanced healthcare system, and the increased prevalence of cancer in the region.

Cancer Pain Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Eli Lilly
• HISAMITSU PHARMACEUTICAL CO., Inc
• Aoxing Pharmaceutical Company, Inc
• GRÜNENTHAL PHARMA GmbH & CO. KG
• PFIZER INC.,
• BIODELIVERY SCIENCES INTERNATIONAL, Inc
• OREXO AB
• Johnson and Johnson
• Medtronic plc
• Novartis AG
• Glaxo SmithKline Plc

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Queries Solved in the Cancer Pain Market Report

• How will the market landscape evolve in the coming years?
• What are the major market trends influencing the market?
• What are the major drivers, opportunities, and restraints in the market?
• Which country is poised to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do factors such as the rising prevalence of cancer impact market growth?
• What are the different types of cancer pain treatments available in the market?
• What are the latest advancements in cancer pain drug research and development?
• What were the major drug approvals to manage cancer pain during the historical period?
• Which segment has the major impact on the cancer pain market size?
• What investments and funding are driving research and development in the market?
• What are the key strategies adopted by leading pharmaceutical companies to gain market share?
• How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?

This product will be delivered within 3-5 business days.